CERE
Income statement / Annual
Last year (2023), Cerevel Therapeutics Holdings, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Cerevel Therapeutics Holdings, Inc.'s net income was -$432.84 M.
See Cerevel Therapeutics Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
08/31/2015 |
08/31/2014 |
08/31/2013 |
08/31/2012 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.72 M
|
$2.40 M
|
$5.24 M
|
$5.37 M
|
| Cost of Revenue |
$5.63 M |
$4.90 M |
$2.73 M |
$397,000.00 |
$0.00 |
$0.00 |
$5.27 M |
$3.02 M |
$6.25 M |
$2.38 M |
| Gross Profit |
-$5.63 M |
-$4.90 M |
-$2.73 M |
-$397,000.00 |
$0.00 |
$0.00 |
-$2.55 M |
-$617,000.00 |
-$1.00 M |
$2.99 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
-0.94 |
-0.26 |
-0.19 |
0.56 |
| Research and Development
Expenses |
$334.64 M
|
$280.26 M
|
$161.86 M
|
$103.30 M
|
$50.29 M
|
$454.65 M
|
$9.68 M
|
$14.16 M
|
$16.40 M
|
$19.16 M
|
| General & Administrative
Expenses |
$112.62 M
|
$87.59 M
|
$58.24 M
|
$45.81 M
|
$33.17 M
|
$28.67 M
|
$15.95 M
|
$14.48 M
|
$15.19 M
|
$12.63 M
|
| Selling & Marketing
Expenses |
-$5.63 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$112.62 M
|
$87.59 M
|
$58.24 M
|
$45.81 M
|
$33.17 M
|
$28.67 M
|
$15.95 M
|
$14.48 M
|
$15.19 M
|
$12.63 M
|
| Other Expenses |
$0.00 |
$6.88 M |
-$5.39 M |
-$3.27 M |
$9,000.00 |
$0.00 |
$5.27 M |
$3.02 M |
$6.25 M |
$0.00 |
| Operating Expenses |
$465.64 M |
$367.85 M |
$220.10 M |
$149.12 M |
$83.46 M |
$465.67 M |
$30.90 M |
$31.66 M |
$37.83 M |
$31.79 M |
| Cost And Expenses |
$465.64 M |
$367.85 M |
$220.10 M |
$149.12 M |
$83.46 M |
$465.67 M |
$36.16 M |
$34.68 M |
$44.08 M |
$34.17 M |
| Interest Income |
$43.87 M |
$9.62 M |
$157,000.00 |
$224,000.00 |
$1.55 M |
$2,036.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$10.57 M |
$9.62 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$30,000.00 |
$68,000.00 |
$0.00 |
$560,000.00 |
| Depreciation &
Amortization |
$5.63 M
|
$4.90 M
|
$2.73 M
|
$397,000.00
|
$177,000.00
|
$76,000.00
|
$657,000.00
|
$1.52 M
|
$1.91 M
|
$2.06 M
|
| EBITDA |
-$441.64 M
|
-$367.85 M
|
-$220.10 M
|
-$149.12 M
|
-$36.84 M
|
-$483.25 M
|
-$27.47 M
|
-$27.74 M
|
-$30.60 M
|
-$26.79 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
-10.1 |
-11.54 |
-5.84 |
-4.99 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
-10.36
|
-12.17
|
-6.22
|
-5.36
|
| Total Other
Income/Expenses Net |
$14.93 M
|
$16.50 M
|
-$5.24 M
|
-$3.05 M
|
-$44.88 M
|
$19.69 M
|
$22,000.00
|
-$63,000.00
|
$80,000.00
|
-$605,000.00
|
| Income Before Tax |
-$432.34 M |
-$351.35 M |
-$225.33 M |
-$152.17 M |
-$128.34 M |
-$463.64 M |
-$28.16 M |
-$29.32 M |
-$32.51 M |
-$29.41 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
-10.35
|
-12.2
|
-6.2
|
-5.48
|
| Income Tax Expense |
$503,000.00 |
$160,000.00 |
-$2.89 M |
-$24,000.00 |
$45,000.00 |
-$161,065.00 |
-$1,000.00 |
-$1,000.00 |
-$1,000.00 |
$3,000.00 |
| Net Income |
-$432.84 M |
-$351.51 M |
-$222.45 M |
-$152.14 M |
-$128.39 M |
-$463.64 M |
-$28.16 M |
-$29.32 M |
-$32.51 M |
-$29.41 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
-10.35 |
-12.2 |
-6.2 |
-5.48 |
| EPS |
-2.67 |
-2.32 |
-1.63 |
-2.07 |
-1.01 |
-164.94 |
-1.98 |
-2.06 |
-2.28 |
-2.07 |
| EPS Diluted |
-2.67 |
-2.32 |
-1.63 |
-2.07 |
-1.01 |
-164.93 |
-4.57 |
-0.81 |
-2.28 |
-2.07 |
| Weighted Average Shares
Out |
$162.06 M
|
$151.27 M
|
$136.58 M
|
$73.64 M
|
$127.12 M
|
$2.81 M
|
$14.24 M
|
$14.24 M
|
$14.24 M
|
$14.24 M
|
| Weighted Average Shares
Out Diluted |
$162.06 M
|
$151.27 M
|
$136.58 M
|
$73.64 M
|
$127.12 M
|
$2.81 M
|
$6.17 M
|
$36.21 M
|
$14.24 M
|
$14.24 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
